SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is currently a focal point of intense investor interest as the community awaits crucial Phase 3 data for its gene editing candidate and monitors the regulatory progress of its cardiac pipeline. With short interest levels remaining elevated, investors are actively debating the potential for a volatile move driven by upcoming clinical readouts and the possibility of a squeeze.

Atomera, Inc. engages in the development, commercialization, and licensing of proprietary processes and technologies for the semiconductor industry. It developed Mears Silicon Technology, which increases performance and power efficiency in semiconductor transistors. The company was founded by Robert Mears on November 26, 2001 and is headquartered in Los Gatos, CA.

Atomera Inc

Atomera is trending as investors aggressively debate the company's long-term commercial potential, fueled by community speculation surrounding its collaboration with major industry players like Synopsys and Applied Materials. While some discuss a potential breakout driven by its Gate-All-Around transistor technology and perceived short-squeeze setups, skeptical voices emphasize the lack of material revenue and concerns over recurring share offerings.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

CRISPR Therapeutics is facing downward pressure following a series of insider share sales, which has sparked frustration among retail investors already concerned by the company's long-term capital efficiency and commercial ramp-up. Despite the negativity, the community remains divided between those calling for a strategic buyout or management change and long-term believers who are leveraging the dip to accumulate shares based on the company's extensive gene-editing pipeline and substantial cash position.

APE fuels culture. Backed by the best club in the world and hundreds of thousands of holders worldwide, it’s the token for digital and IRL communities, builders, creators, collectors, gamers, and beyond.  APE is the native gas token of ApeChain and is available across multiple ecosystems including Ethereum, Arbitrum, Solana and HyperLiquid.z  ApeCoin's mission is is to supercharge its ecosystem by supporting high-quality builders &amp; reinforcing 3 core pillars: ApeChain, Bored Ape Yacht Club, and Otherside.

ApeCoin

ApeCoin is seeing a surge in investor attention and high-volume volatility, fueled by the launch of ApeChain and the influx of new on-chain projects. The community remains divided, with some traders highlighting the token's aggressive, flow-driven momentum while others express frustration over long-term price performance and historical dilution concerns.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo is experiencing heightened volatility and strong community interest following a strategic collaboration with NVIDIA and Los Alamos National Laboratory, which is fueling excitement around the company's role in powering AI infrastructure. While bullish investors point to these institutional partnerships and potential regulatory catalysts as long-term drivers, others remain cautious, citing the company's pre-revenue status and recent insider selling activity.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is seeing a massive surge in market interest, driven by speculation over potential partnerships with major hyperscalers and its critical role in AI optical interconnects. The community is actively discussing the stock's parabolic volume and momentum, with longs celebrating the potential for a sustained breakout while shorts remain under intense pressure.

X-Energy, Inc. operates as an energy company The firm focuses on modular nuclear reactors and fuel technology for clean energy generation. The company was founded by Kam Ghaffarian and Eben Mulder on 2009 and is headquartered in Rockville, MD.

X-Energy Inc. - Ordinary Shares- Class A

X-energy Inc

X-energy is capturing significant market attention following its public debut, with investors closely watching the nuclear developer's strategic partnerships with major tech giants like Amazon to fuel AI infrastructure demand. While the community is debating the stock's valuation and long-term viability, the conversation is largely driven by high initial demand and the broader narrative surrounding the role of small modular reactors in solving energy bottlenecks.

iShares Trust - iShares Semiconductor ETF

iShares Semiconductor ETF

iShares Semiconductor ETF is experiencing intense volatility and record-breaking volume as traders debate whether the sector's parabolic run represents an unsustainable bubble or a continued momentum-driven surge. Community sentiment is deeply divided, with many actively hedging against a potential blow-off top while others remain focused on the sector's long-term dominance in AI infrastructure.

Dumb SEND IT

$DSIT is generating significant buzz among community members who are positioning the token as a high-momentum weekend runner, with active discussions focused on breaking through previous market cap milestones. Investors are coordinating social media engagement and highlighting developer-led airdrops to build momentum, while comparisons to other meme coin cycles drive speculation about its growth potential.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending as community members aggressively debate its long-term utility and potential for a breakout, driven by anticipation surrounding industry conferences and rumors of strategic partnerships. While some investors view the asset as a undervalued hidden gem for long-term holding, others express frustration over stagnant price action and caution against speculative hype.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

iBio (IBIO) Projected to Post Quarterly Earnings on Friday

iBio (NASDAQ:IBIO) will be releasing its Q3 2026 earnings before the market opens on Friday, May 1. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-1-ibio-inc-stock-3...

iBio (NASDAQ:IBIO) Earns Buy Rating from Chardan Capital

Chardan Capital restated a "buy" rating and issued a $5.00 target price on shares of iBio in a report on Thursday...

iBio Details Generative AI Antigen Platform to Speed GPCR Antibody Discovery and Close Trust Gap

iBio (NASDAQ:IBIO) is seeking to narrow what it views as a growing trust gap between the promise of generative AI in drug discovery and the high cost and long timelines of bringing a drug to market...

<ul class="summary-bullets"><li>iBio stated that it expects to dose the first participant in Australia with IBIO-600 in the second quarter.</li><li>The company’s previously announced pre-clinical studies showed that IBIO-600 demonstrated a pharmacologic activity and an extended half-life of 40–52 days following a single administration in non-human primates.</li><li>iBio stated that it also observed an increase of over 5.1% in lean muscle mass during its pre-clinical studies.</li></ul>iBio Inc. (IBIO) shares gained nearly 10% in Wednesday’s pre-market trade after the company announced that its muscle-preserving drug has received approval for the first in-human trial in Australia.iBio stated that IBIO-600 has been approved by Australia’s Therapeutic Goods Administration (TGA) to initiate a Phase 1 study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of the drug in overweight and obese adult participants.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/IBIO">iBio</a> trended in the ‘bullish’ territory at the time of writing.<h2 class="st-heading-2">First Participant Expected To Be Dosed In Q2</h2>iBio stated that it expects to dose the first participant in Australia with IBIO-600 in the second quarter (Q2).“While GLP-1 therapies have transformed the treatment landscape, significant gaps remain, particularly around the loss of muscle mass. We believe IBIO-600 has the potential to address this unmet need,” said iBio CEO Martin Brenner.iBio’s previously announced pre-clinical studies showed that IBIO-600 demonstrated a pharmacologic activity and an extended half-life of 40–52 days following a single administration in non-human primates.The company also observed an increase of over 5.1% in lean muscle mass during its pre-clinical studies.“These findings, observed alongside reductions in fat mass and durable effects over time, support the advancement of IBIO-600 into clinical development,” the company added.<h2 class="st-heading-2">What Does IBIO-600 Do?</h2>IBIO-600 is a long-acting monoclonal antibody that targets myostatin and GDF11, which are proteins that inhibit skeletal muscle growth.It is designed to help preserve lean muscle and improve body composition in patients with obesity. iBio stated that it has the potential to be used alongside GLP-1 treatments to counter muscle loss during weight reduction.<a href="https://stocktwits.com/symbol/IBIO">IBIO stock</a> is up 9% year-to-date and 40% over the past 12 months. The Vanguard Total Stock Market Index Fund ETF (VTI) is up 31% over the past 12 months, while the Vanguard Extended Market Index Fund ETF (VXF) is up 36% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dal-stock-soars-delta-air-lines-q1-results-beat-expectations/cZJODXcRIqr">DAL Stock Soars As Delta Air Lines Beats Q1 Expectations, CEO Says ‘Demand Remains Strong’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

IBIO Stock Is Soaring Today After iBio's Muscle-Preserving Drug Receives Approval For Human Trial In Australia

iBio stated that IBIO-600 has been approved by Australia’s Therapeutic Goods Administration to initiate a Phase 1 study in overweight and obese adult participants.

Equity

iBio, Inc. (NASDAQ:IBIO) Given Average Recommendation of "Buy" by Analysts

iBio, Inc. (NASDAQ:IBIO - Get Free Report) has received a consensus recommendation of "Buy" from the six research firms that are presently covering the company, Marketbeat.com reports. One research...

iBio (NASDAQ:IBIO) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen upgraded iBio from a "sell" rating to a "hold" rating in a report on Saturday...

Insider Buying: iBio (NASDAQ:IBIO) CFO Buys 24,835 Shares of Stock

iBio, Inc. (NASDAQ:IBIO - Get Free Report) CFO Felipe Duran bought 24,835 shares of the stock in a transaction dated Thursday, March 19th. The stock was purchased at an average price of $2.02 per...

iBio (NASDAQ:IBIO) CFO Felipe Duran Acquires 24,835 Shares

iBio, Inc. (NASDAQ:IBIO - Get Free Report) CFO Felipe Duran bought 24,835 shares of the company's stock in a transaction dated Thursday, March 19th. The stock was purchased at an average price of...

Martin Brenner Purchases 12,336 Shares of iBio (NASDAQ:IBIO) Stock

iBio, Inc. (NASDAQ:IBIO - Get Free Report) insider Martin Brenner purchased 12,336 shares of the stock in a transaction dated Thursday, March 19th. The stock was purchased at an average cost of $2.02...

iBio (NASDAQ:IBIO) Cut to Sell at Wall Street Zen

Wall Street Zen lowered iBio from a "hold" rating to a "sell" rating in a research report on Saturday...

iBio, Inc. is an AI-driven innovator that develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard to target cancers, and other diseases. It focuses on decreasing drug failures, shortening drug development timelines and opening up new frontiers against the most promising targets. The company was founded on April 17, 2008 and is headquartered in San Diego, CA.

Current Price	$1.68
Prev Close	$1.81
Open	$1.80
Dividend Yield	0.00%
50-Day Moving Average	$2.26
Beta	1.39
Avg. Volume	1.12M
PE Ratio	-1.80

52-Week High	$3.82
52-Week Low	$0.5562
Market Capitalization	$65.42M
EPS (Annual)	-$1.75
Price to Book	0.96
Revenue Per Employee	$20,000.00

IBIO
iBio Inc

Feed

News

Sentiment

Fundamentals

Info

Latest IBIO News

IBIOiBio Inc